Artelo Biosciences Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Artelo Biosciences Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for ART12 (Approved).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| ART26 | n/a | n/a | Preclinical | Public pipeline row |
| ART27 | n/a | n/a | Phase 2 | Public pipeline row |
| FABP12 | multiple conditions and diseases | n/a | n/a | Public pipeline row |
| What are FABPs? | n/a | n/a | n/a | Public pipeline row |
| SBFI103 | n/a | n/a | n/a | Public pipeline row |
| ART12 | n/a | n/a | Approved | Public pipeline row |
| SBFI26 | n/a | n/a | n/a | Public pipeline row |
| ART27.13 | Cancer-Related Anorexia and Cachexia | n/a | n/a | Public pipeline row |
Estimated cash runway: Runway 6-12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| No public trial rows are loaded yet. | ||||
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.